Mission
Our mission is to improve the lives of people living with chronic lymphocytic leukemia (CLL) by making non-chemotherapy treatments safer and more effective. We have an additional focus on developing treatments for CLL-associated and primary autoimmune hemolytic anemia.
Who We Are
An integral part of the OSUCCC – James Experimental Hematology Lab — one of the largest leukemia research centers in the country — the Rogers Lab is led by Kerry Rogers, MD, a physician scientist who specializes in chronic lymphocytic leukemia (CLL) and hairy cell leukemia (HCL). She is board certified in internal medicine as well as hematology and medical oncology. Dr. Rogers has expertise in therapies for CLL and is the principal investigator on clinical trials studying chemotherapy-free combination regimens for this disease. These focus on strategies for time-limited treatment or elimination of molecular resistance. She is also involved in research on targeted agents in HCL. Her laboratory work focuses on the use of B-cell receptor signal antagonists in mouse models of autoimmune hemolytic anemia and correlative studies for clinical trials.
Kerry Rogers, MD
Assistant Professor, Division of Hematology
Laura Martz
Research Associate 1
Clinical Trials
A Multicenter Study of Ibrutinib Resistance Development and Intervention With Venetoclax (Phase 2) (NCT03513562)
Phase 1B Open-Label Study of VAY736 and Ibrutinib in Patients With Chronic Lymphocytic Leukemia on Ibrutinib Therapy (NCT03400176)
A Phase II Study of Venetoclax in Combination With Dose-Adjusted EPOCH-R for Patients With Richter's Syndrome (NCT03054896)
Obinutuzumab, Ibrutinib and Venetoclax for Relapsed and Previously Untreated Chronic Lymphocytic Leukemia (NCT02427451)
A Multicenter Phase 2 Study of The Bruton’s Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) for Treatment of Relapsed Hairy Cell Leukemia (NCT01841723)